IP Library Patent Application 11228462
Patent Application
App. No. 11/228,462

System for cell enrichment

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/228,462
Filed
Sep 15, 2005
Art Unit
1632
USPC
435/325
Abstract

The present invention provides systems useful for the enrichment of analytes, for example, cells of selected types, including but not limited to blood cells, stem cells, and pathogens, in samples. The invention also provides methods for analyzing the condition of a patient based on characteristics identified through analysis of the analytes in case and control samples.

Claims (33)

1 . A system comprising a separation module adapted for removal of more than 99.5% of enucleated cells from a blood sample and retention of more than 99% of nucleated cells from a blood sample.

2 . The system of claim 1 further comprising an analyzer fluidly coupled to said separation module adapted to analyze one or more of said nucleated cells and a database for storing analysis data.

3 . A system comprising:

one or more first enrichment regions, wherein said enrichment regions comprise a two dimensional plurality of obstacles defining a first fluid flow path for a first analyte and a second fluid flow path for a second analyte wherein said first analyte and said second analyte have different hydrodynamic diameters;

an analyzer fluidly coupled to said one or more enrichment regions for obtaining data on said first analyte or said second analyte; and

a database for storing said data.

4 . The system of claim 3 wherein said first analyte is selected from the group consisting of a red blood cell (RBC), a fetal RBC, a trophoblast, a fetal fibroblast, a white blood cell (WBCs), an infected WBC, a stem cell, an epithelial cell, an endothelial cell, a stem cell, a cancer cell, a viral cell, a bacterial cell, and protozoan.

5 . The system of claim 3 wherein said cell type is found in vivo at a concentration of less than 1×10 −3 cells/μL.

6 . The system of claim 3 wherein gaps between obstacles in said first enrichment region is at most 1000 microns.

7 . The system of claim 3 further comprising one or more second enrichment regions comprising, wherein said second enrichment regions captures said first analyte or said second analyte, and wherein said second enrichment region is in fluid communication with said first enrichment region.

8 . The system of claim 3 wherein said one or more first enrichment regions are adapted to retain at least 99% of said first analyte.

9 . The system of claim 3 wherein said one or more first enrichment regions are adapted to increase concentration of said first analyte by at least a factor of 100,000.

10 . A method for identifying a characteristic associated with a condition in a patient comprising:

obtaining a plurality of control samples;

obtaining a plurality of case samples;

applying each of said samples to a device comprising a plurality of obstacles that deflect a first analyte from said sample in a direction away from a second analyte of said blood sample wherein said first analyte and said second analyte have a different hydrodynamic diameter;

analyzing said first analyte from said samples to determine a characteristic of said first analyte; and

performing an association study based on said characteristic.

11 . The method of claim 10 wherein said characteristic is the presence or absence of said first analyte.

12 . The method of claim 10 wherein said characteristic is the number of said first analyte.

13 . The method of claim 10 wherein said characteristic is the morphology of said first analyte.

14 . The method of claim 10 wherein said characteristic is the genotype of said first analyte.

15 . The method of claim 10 wherein said characteristic is the proteome of said first analyte.

16 . The method of claim 10 wherein said characteristic is the RNA composition of said first analyte.

17 . The method of claim 10 wherein said characteristic is the level of gene expression of said first analyte.

18 . The method of claim 10 wherein said plurality of control samples comprises at least 100 control samples.

19 . The method of claim 10 wherein said plurality of case samples comprises at least 100 case samples.

20 . The method of claim 10 wherein said control samples and case samples are blood samples.

21 . The method of claim 20 wherein each blood sample comprises less than 100 mL of blood.

22 . The method of claim 10 wherein said analyte is a cell type.

23 . The method of claim 22 wherein said analyte is an epithelial cell, a cancer cell, or a fetal cell.

24 . The system of claim 3 wherein said obstacles deterministically direct said fluid flow for said first and second analytes.

25 . The system of claim 24 wherein said array of obstacles define gaps which direct the flow of sample unequally into subsequent gaps.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2011
From: TONER, MEHMET
To: THE GENERAL HOSPITAL CORPORATION; GPB SCIENTIFIC, LLC
Reel/Frame 027044/0055 →
QUIT CLAIM ASSIGNMENT Recorded Oct 11, 2011
From: THE GENERAL HOSPITAL CORPORATION
To: TONER, MEHMET
Reel/Frame 027046/0173 →
CHANGE OF NAME Recorded Oct 8, 2007
From: LIVING MICROSYSTEMS, INC.
To: ARTEMIS HEALTH, INC.
Reel/Frame 019931/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2006
From: TONER, MEHMET
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 017024/0282 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2006
From: KAPUR, RAVI; HUANG, LOTIEN R.
To: LIVING MICROSYSTEMS INC.
Reel/Frame 017024/0289 →